Full Press Release Details
NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
• Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 4:00 p.m. ET on Tuesday, November 10.
• Stifel 2026 Healthcare Conference in New York, NY on Wednesday, November 11, 2026. Michael Davidson, M.D., Chief Executive Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:20 a.m. ET on Wednesday, November 11.
• Jefferies Global Healthcare Conference in London, UK on Wednesday, November 18, 2026. John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:30 a.m. GMT on Wednesday, November 18.
Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.